Ipratop Nebuliser Solution - Nebuliser Solution Ipratropium Bromide - 250mcg/ml 1 10's Ampoules(s) / 10's Ampoules Incepta Pharmaceuticals Ltd. Introduction: Ipratop Nebuliser Solution is an anticholinergic medicine. It is used in the treatment of chronic obstructive pulmonary disease and asthma. Ipratop Nebuliser Solution is only for the inhalational purpose, so do not swallow the capsule. The first dose is given under medical supervision to prevent the side effects happen during first use. For better results, it is suggested to take it at the same time every day. The dose and how often you take it depends on what you are taking it for. Your doctor will decide how much you need to improve your symptoms. You should take this medicine... Uses of Ipratop Nebuliser Solution: Chronic obstructive pulmonary disease (COPD)Asthma Side effects of Ipratop Nebuliser Solution: Dryness in mouthDry nose How to use Ipratop Nebuliser Solution: Use this medicine in the dose and duration as advised by your doctor. Check the label for directions before use. Twist off the top of the respule/transpule and squeeze all the liquid into the nebulizer. It should be used right away after opening. How Ipratop Nebuliser Solution works: Ipratop Nebuliser Solution is an anticholinergic medication. It works by relaxing the muscles in the airways and widens the airways. This makes breathing easier. What if you forget to take Ipratop Nebuliser Solution?: If you miss a dose of Ipratop Nebuliser Solution, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular schedule. Do not double the dose. Indication: Asthma, chronic obstructive pulmonary disease, chronic bronchitis, emphysema. Adult Dose: Inhalation Asthma; Chronic obstructive pulmonary disease Adult: As Inhaler: Adults: 1-2 puffs (20 mg/puff) 3-4 times daily. Single doses of up to 80 mcg may be required in some patients. As nebulized soln 250-500 mcg 3-4 times daily. Child Dose: Inhalation Asthma; Chronic obstructive pulmonary disease Child: As metered-dose aerosol: <6 yr 20 mcg tid; 6-12 yr 20-40 mcg tid. As soln for nebulisation: <6 yr For acute asthma: 125-250 mcg, given no more often than 6 hrly up to a total dose of 1 mg. 6-12 yr For acute and chronic asthma: 250 mcg, repeated as necessary up to a total dose of 1 mg. Contraindication: Ipratropium Bromide solution should not be taken by patients with known hypersensitivity to atropine or its derivatives or to any other component of the product. Mode of Action: Ipratropium bromide blocks the action of acetylcholine at parasympathetic sites in bronchial smooth muscle causing bronchodilation. Precaution: Bladder neck obstruction, narrow-angle glaucoma or patients susceptible to glaucoma, prostatic hyperplasia. Protect patient's eyes from nebulised drug. Renal and hepatic impairment. Pregnancy, lactation, children, elderly. Side Effect: Dry mouth, urinary retention, buccal ulceration, paralytic ileus, headache, nausea, constipation, paradoxical bronchospasm, immediate hypersensitivity reactions (urticaria, angioedema), acute angle-closure glaucoma. Potentially Fatal: Anaphylactic reactions, atrial fibrillation, supraventricular tachycardia. Interaction: Increased toxicity with other anticholinergic drugs.